Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
NNMT Regulates Cancer Immunity and Is a Potential Prognostic Biomarker in Gastric and Colorectal Cancers
31 Pages Posted: 23 Jun 2019
More...Abstract
Background: Nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that catalyzes the N-methylation of nicotinamide, has been shown to be critical for promoting cancer progression, but little is known its role in gastric and colorectal cancers.
Methods: We explored the role of NNMT in predicting prognosis and immune infiltration of gastric and colorectal cancers. Data was obtained from RNAseq Atlas, Oncomine, tumor Immune Estimation Resource (TIMER) databases, Kaplan-Meier plotter, PrognoScan database and Gene Expression Profiling Interactive Analysis (GEPIA).
Findings: NNMT is overexpressed in gastric and colorectal cancers compared to adjacent normal tissues. High NNMT expression was significantly associated with worse outcome in gastric and colorectal cancer patients. However, high expression of NNMT was highly predictive of effectual 5-fluorouracil (5-FU) treatment in HER2 negative gastric cancer patients. Furthermore, there were significant positive correlations between NNMT expression and immune cells infiltration in gastric and colorectal cancers. Conversely, NNMT did not exert any significant effect on prognosis and immune infiltration in lung cancer.
Interpretation: NNMT could be a prognostic factor for predicting clinical outcomes and immune infiltration, as well as a molecular target for the treatment of gastric and colorectal cancers.
Funding: This work was supported in part by funding from the National Natural Science Foundation of China (No. 81502598).
Declaration of Interest: The authors declare that they have no competing interests.
Ethical Approval: Not required.
Keywords: NNMT; immune infiltration; lymphocytes; prognosis; gastric cancer; colorectal cancer
Suggested Citation: Suggested Citation